Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PONAZA: Ponatinib and 5-Azacitidine in Advanced CML
NCT03895671Phase 2Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Jun 2019
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ponatinib and azacitidine in chronic myeloid leukemia (CML) (2 arms), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Overall Survival at 2 years. Started Jun 2019; status: completed.
02
Drugs
ponatinibazacitidine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03895671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895671.